The Expression of Proto-Oncogene () Plays a Central Role in the Oncogenic Mechanism Involved in the Development and Progression of Prostate Cancer.

The () is proto-oncogene that is classified as a member of the transcription factor family, which has been found to be consistently overexpressed in about half of the patients with clinically significant prostate cancer (PCa). The overexpression of can mostly be attributed to the fusion of the and () genes, and this fusion is estimated to represent about 85% of all gene fusions observed in prostate cancer. Clinically, individuals with gene fusion are mostly documented to have advanced tumor stages, increased mortality, and higher rates of metastasis in non-surgical cohorts.